Insights Into Breast Cancer

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease

Southwest March 1, 2021

Faculty Chair

Mark Pegram, MD

Stanford Women’s Cancer Center, Palo Alto, CA

Central April 7, 2021

Faculty Chair

Debu Tripathy, MD

MD Anderson Cancer Center, Houston, TX

Northeast May 3, 2021

Faculty Chair

Adam Brufsky, MD

University of Pittsburgh, Pittsburgh, PA

Southeast May 6, 2021

Faculty Chair

Reshma Mahtani, DO

University of Miami Health System, Deerfield Beach, FL

Northwest May 17, 2021

Faculty Chair

Mark Pegram, MD

Stanford Women’s Cancer Center, Palo Alto, CA

Southeast June 17, 2021

Faculty Chair

Reshma Mahtani, DO

University of Miami Health System, Deerfield Beach, FL

Northeast August 16, 2021

Faculty Chair

Sara Tolaney, MD

Dana-Farber Cancer Institute, Boston, MA

Midwest September 2021

Faculty Chair

TBC

More Information

  • Virtual Series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual Series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual Series
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Virtual Series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual Series
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

More Information

  • Virtual Series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual Series
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, Indiana, Ohio

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of breast cancer
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained:
    • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
    • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
    • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.